Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAIB: Sequential Anti-angiogenic Therapy in Biliary Tract Cancer
NCT07025174Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iparomlimab + tuvonralimab in biliary tract cancer (BTC) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Progression-Free Survival of Second-Line Treatment at 24 months. Started Jun 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07025174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025174.